Second quarter and first half 2020 financial report

21. Aug 2020 | 2 min read

Moss, 21 August 2020

Gentian Diagnostics AS announces its results for the second quarter and first half of 2020. The highlights include:

  • Record sales revenues of MNOK 16.6 in 2Q20, up from MNOK 10.2 in 2Q19
  • Sales growth in 2Q20 of 64 % is especially based on Cystatin C sales in Asia. Sales in the quarter grew by 44 % YoY on a currency neutral basis
  • Successful release of fPELA® turbo, which is marketed by our partner BÜHLMANN
  • Gentian awarded up to MNOK 8.0 in funding to support the development of a high-throughput SARS-CoV-2 antibody test
  • New scientific publications propose calprotectin as a promising biomarker for the management of COVID-19 patients, which represents a new opportunity for our GCAL® assay

Please find the report and results presentation here:

GDAS Interim Report 2Q 2020

GDAS Interim Presentation 2Q 2020

 

For further information, please contact:

Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

MeldingsID: 511876
UtstederID: GENT-ME
Marked: Merkur Market

You may also read


Jun 25, 2021 - Kristin Hart

Gentian Diagnostics was today listed on the Oslo Stock Exchange

“We made a promise to our shareholders when we were listed on Euronext Growth that we would aim for the main..

Jun 24, 2021 - Kristin Hart

Gentian Diagnostics ASA – Approval and publication of prospectus, and transfer of listing from Euronext Growth (Oslo) to Oslo Børs

Moss, 24 June 2021 Reference is made to the announcement made by Gentian Diagnostics ASA (the "Company") on 7..

Jun 23, 2021 - Kristin Hart

Transfer of shares to Oslo Børs approved, prepared for accelerated growth

Moss, 23.06.2021 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative and..